Tumor Biology

, Volume 34, Issue 2, pp 859–864 | Cite as

The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma

  • George Tsirakis
  • Constantina A. Pappa
  • Maria Kaparou
  • Anna Boula
  • Vaitsa Katsomitrou
  • Athina Xekalou
  • Stavroula Kyriakaki
  • Michael G. Alexandrakis
Research Article
First Online:
Received:
Accepted:

Abstract

Soluble interleukin-6 receptor (sIL-6R) is part of IL-6 receptor that may stimulate cells that do not express the whole molecule. It may enhance myeloma cell proliferation and furthermore angiogenesis. The aim of the study was to evaluate the clinical significance and the relationship between serum levels of sIL-6R, with various stimulators of angiogenesis, such as hepatocyte growth factor (HGF) and interleukin-18 (IL-18) and with markers of proliferation, such as beta-2 microglobulin (B2M) levels and plasma cell Ki-67 proliferation index in the bone marrow, in patients with multiple myeloma (MM). We studied 45 newly diagnosed MM patients. Serum levels of sIL-6R, HGF, IL-18, and B2M and Ki-67 proliferation index (Ki-67 PI) in bone marrow’s plasma cells were determined. The mean concentrations of sIL-6R, HGF, IL-18, and B2M and the value of Ki-67 were significantly higher in the patients compared to controls and with increasing disease stage. sIL-6R was strongly positively correlated with HGF, IL-18, B2M, and Ki-67 PI. There is a positive correlation between plasma cell growth, as determined by Ki-67 PI, and different angiogenic cytokines, such as HGF and IL-18, with sIL-6R. This relationship suggests the significant role of these cytokines in the proliferation and disease activity in MM patients.

Keywords

Angiogenesis Cytokines Multiple myeloma 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

None

References

  1. 1.
    Klein B, Seckinger A, Moehler T, Hose D. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res. 2011;183:39–86.PubMedCrossRefGoogle Scholar
  2. 2.
    Otjacques E, Binsfeld M, Noel A, Beguin Y, Cataldo D, Caers J. Biological aspects of angiogenesis in multiple myeloma. Int J Hematol. 2011;94:505–18.PubMedCrossRefGoogle Scholar
  3. 3.
    Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol. 1990;1:199–206.PubMedGoogle Scholar
  4. 4.
    Endl E, Steinbach P, Knüchel R, Hofstädter F. Analysis of cell cycle-related Ki-67 and p120 expression by flow cytometric BrdUrd-Hoechst/7AAD and immunolabeling technique. Cytometry. 1997;29:233–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Kausch I, Lingnau A, Endl E, Sellmann K, Deinert I, Ratliff TL, Jocham D, Sczakiel G, Gerdes J, Böhle A. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer. 2003;105:710–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990;17:489–503.PubMedCrossRefGoogle Scholar
  7. 7.
    Lai R, Medeiros LJ, Wilson CS, Sun NC, Koo C, McCourty A, Brynes RK. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol. 1998;11:642–7.PubMedGoogle Scholar
  8. 8.
    Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki K, Niniraki M, Stathopoulos E. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol. 2004;27:8–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382–7.PubMedGoogle Scholar
  10. 10.
    Sun Y, Naito Z, Ishiwata T, Maeda S, Sugisaki Y, Asano G. Basic FGF and Ki-67 proteins useful for immunohistological diagnostic evaluations in malignant solitary fibrous tumor. Pathol Int. 2003;53:284–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Drach J, Gattringer C, Glassl H, Drach D, Huber H. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma. Hematol Oncol. 1992;10:125–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol. 2004;57:856–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46:1223–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol. 2001;167:1644–53.PubMedGoogle Scholar
  16. 16.
    Börset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood. 1996;88:3998–4004.PubMedGoogle Scholar
  17. 17.
    Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica. 2000;85:800–5.PubMedGoogle Scholar
  18. 18.
    Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol. 2003;72:229–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Seidel C, Børset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood. 1998;91:806–12.PubMedGoogle Scholar
  20. 20.
    Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol. 2007;4:329–35.PubMedGoogle Scholar
  21. 21.
    Dinarello CA. Interleukin-18. Methods. 1999;19:121–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999;103:11–24.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang B, Wang Y, Zheng GG, Ma XT, Li G, Zhang FK, Wu KF. Clinical significance of IL-18 gene over-expression in AML. Leuk Res. 2002;26:887–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol. 2003;82:19–23.PubMedGoogle Scholar
  25. 25.
    Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer. 1998;82:1860–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol. 2006;63:321–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy Jr JD. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood. 2012;119:503–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol. 2011;2011:721608.PubMedGoogle Scholar
  29. 29.
    Kanavaros P, Stefanaki K, Vlachonikolis J, Papalazarou D, Rontogianni D, Arvanitis D, Antonakopoulos G, Gorgoulis V, Bai M, Agnantis NJ. Immunohistochemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma. Anticancer Res. 2000;20:4619–25.PubMedGoogle Scholar
  30. 30.
    Tsirakis G, Pappa CA, Spanoudakis M, Chochlakis D, Alegakis A, Psarakis FE, Stratinaki M, Stathopoulos EN, Alexandrakis MG. Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma. Eur J Intern Med. 2012;23:368–73.PubMedCrossRefGoogle Scholar
  31. 31.
    Tsirakis G, Pappa CA, Psarakis FE, Fragioudaki M, Tsioutis C, Stavroulaki E, Boula A, Alexandrakis MG. Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma. Med Oncol. 2012;29(4):2396–401.PubMedCrossRefGoogle Scholar
  32. 32.
    Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sørensen FB, Abildgaard N. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol. 2005;128:210–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000;95:388–92.PubMedGoogle Scholar
  34. 34.
    Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol. 2002;116:796–802.PubMedCrossRefGoogle Scholar
  35. 35.
    Pages F, Berger A, Lebel-Binay S, Zinzindohoue F, Danel C, Piqueras B, Carriere O, Thiounn N, Cugnenc PH, Fridman WH. Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett. 2000;75:9–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith Jr MF, Foley E, Moskaluk CA, Bickston SJ, Cominelli F. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol. 19991;162:6829–35.Google Scholar
  37. 37.
    Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med. 2008;86:785–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Cho ML, Jung YO, Moon YM, Min SY, Yoon CH, Lee SH, Park SH, Cho CS, Jue DM, Kim HY. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett. 2006;103:159–66.PubMedCrossRefGoogle Scholar
  39. 39.
    Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, Pappa C, Liapi D, Petreli E, Roussou P, Kyriakou DS. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res. 2004;28:259–66.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • George Tsirakis
    • 1
  • Constantina A. Pappa
    • 2
  • Maria Kaparou
    • 1
  • Anna Boula
    • 2
  • Vaitsa Katsomitrou
    • 1
  • Athina Xekalou
    • 3
  • Stavroula Kyriakaki
    • 1
  • Michael G. Alexandrakis
    • 1
  1. 1.Department of HematologyUniversity Hospital of HeraklionHeraklionGreece
  2. 2.Department of HematologyVenizelion General Hospital of HeraklionHeraklionGreece
  3. 3.Department of PathologyUniversity Hospital of HeraklionHeraklionGreece

Personalised recommendations